AXL and non-small cell lung carcinoma: R428 (bemcentinib, BGB324), a selective small-molecule inhibitor of AXL, is currently being evaluated in phase II trials for the treatment of non-small-cell lung cancer (NSCLC) (17) and acute myelocytic leukemia (AML).